CCM
AVDL

Consonance Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Consonance Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-630,178
Closed -$9.45M – 27
2014
Q2 		$9.45M Sell
630,178
-417,398
-40% -$5.03M 1.41% 22
2014
Q1 		$14M Buy
+1,047,576
New +$11.2M 2.09% 18

Other funds holding AVDL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.23B AUM 51.32% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Consonance Capital Management's AVDL Position: Q3 2014 in Review

Consonance Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q3 2014, closing a stake of 630,178 shares — an estimated $9.45M sold.

Consonance Capital Management first reported a position in AVDL in Q1 2014 and held it in 2 quarters. The position peaked at $14M in Q1 2014. 71 funds tracked by Wall St. Rank hold AVDL as of Q3 2014.

  • Consonance Capital Management reported no remaining Avadel Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Consonance Capital Management sold 630,178 Avadel Pharmaceuticals shares in Q3 2014, an estimated $9.45M.
  • Consonance Capital Management first reported a position in Avadel Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Consonance Capital Management's Avadel Pharmaceuticals position peaked at $14M in Q1 2014.
  • 71 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2014.

Based on Consonance Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.